A practical reference on receptor agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-21 and is reviewed periodically as new material appears.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
== Research == Multiple studies have shown that LDN has promise as a treatment for chronic pain, some autoimmune disorders, and cancers. Studies on the efficacy of LDN for multiple sclerosis have been inconclusive. Clinical trials for its use as treatment of fibromyalgia were initiated in 2021. LDN is also being studied in long COVID. A 2018 therapeutic utilization review concluded that LDN may be an appropriate option for treatment of fibromyalgia and irritable bowel syndrome, but that "proper clinical trials are needed in order to establish evidence that could lead to correct indications, mode of administration, and other aspects necessary for effective clinical pharmacology of [low-dose naltrexone]." The UK's National Health Service echoed this sentiment in 2020. In a 2013 paper published in Arthritis & Rheumatology, authors Jarred Younger and Sean Mackey reported reduced circulating pro‑inflammatory cytokines and self‑reported pain in fibromyalgia patients using LDN. A 2018 review summarized mixed trial outcomes and emphasized methodological limitations. A 2023 systematic review published in the Australian Journal of General Practice found that preliminary research into the use of LDN as a treatment for fibromyalgia is promising. All clinical studies examined showed statistically significant improvements in pain and pain tolerance with mild side effects; however, sample sizes were small and the evidence is inconclusive.
=== Ownership and promotion === Knoll pharmaceuticals, originally founded in Germany in 1886, became a subsidiary of BASF (a German chemical company) in 1975. It was under their control when Vicoprofen was originally developed and approved. In March 2000, Knoll Pharmaceuticals and Abbott Laboratories, an American health care company, announced a co-promotion agreement for Vicoprofen, in which Abbott would promote Vicoprofen to its network of buyers, including physicians, hospitals, and surgical centers. In June 2002, Abbott Laboratories, paid $6.9 billion to acquire the entire Knoll pharmaceutical unit from BASF, including Vicoprofen.
Pacinian corpuscles are rapidly adapting phasic receptors that detect gross pressure changes and vibrations in the skin. Pacinian corpuscles have a large receptive field on the skin's surface with an especially sensitive center. The corpuscles are especially sensitive to vibrations, which they can sense even centimeters away. Their optimal sensitivity is 250 Hz, and this is the frequency range generated upon fingertips by textures made of features smaller than 1 μm. Pacinian corpuscles respond when the skin is rapidly indented but not when the pressure is steady (due to the capsule). It is thought that they respond to high-velocity changes in joint position. They have also been implicated in detecting the location of touch sensations on handheld tools.
N0: No facial nerve involvement N1: Upper facial nerve involvement (temporal or zygomatic branches) N2: Lower facial nerve involvement (buccal, mandibular or cervical) N3: All branches affected Soft tissue
For 0D MOF structures, polycationic nodes can act as semiconductor quantum dots which can be activated upon photostimuli with the linkers serving as photon antennae. Theoretical calculations show that MOFs are semiconductors or insulators with band gaps between 1.0 and 5.5 eV which can be altered by changing the degree of conjugation in the ligands. Experimental results show that the band gap of IRMOF-type samples can be tuned by varying the functionality of the linker. An integrated MOF nanozyme was developed for anti-inflammation therapy.
Sources: en.wikipedia.org
=== Grand Lodge of South Carolina === On March 27, 1818, the Grand Lodge of South Carolina chartered La Constancia Lodge, No. 50. On March 31, 1820, they chartered La Amenidad Lodge, No. 52. Both of these were chartered in Havana. In 1821, the Grand Lodge of Ancient Freemasons sent a communication to the Grand Lodge of South Carolina that a new Grand Lodge had been formed in Cuba, and La Amenidad Lodge, No. 52 had expressed its desire to transfer to the new Grand Lodge. The Grand Lodge of South Carolina accepted the arrangement. However, La Constancia Lodge, No. 50, remained a part of the Grand Lodge of South Carolina until its members surrendered its warrant around the year 1824, stating that their decision was made "in consequence of the religious and political persecutions to which they were subjected."
=== Cancer biology === With technological advances, this assay is becoming very beneficial especially in the cancer biology realm. A study was performed to better understand the role that claudin-7, a family of tight junction proteins, plays in cell migration in a type of human lung cancer cells. Due to the slower migration rate of claudin-7 knockdown cells, it supports the idea that this protein is important in cell migration an cell's ability to metastasize. Cells undergo sheet migration due to a multitude of signals and mechanisms when trying to close a wound, which is believed to be similar to the underlying mechanisms involved in metastasis.
=== Breeds at CIRB === The main local breeds at CIRB are the Murrah and Nili-Ravi breeds, the former is researched at main campus at Hisar and the later is bred at the Bir Dosanjh sub-station. It also networks with other institutes to undertake research, and collate and disseminate information on the 10 recognised breeds of the Indian river buffalo: Bhadawari, Banni, Jafarabadi, Marathwadi, Mehsana, Murrah, Nagpuri, Nili-Ravi, Pandharpuri, Surti, and Toda and Swamp buffalo found in Assam. Buffalo milk has 58% more calcium, 40% more protein and 43% less cholesterol than cow milk. Buffalo milk is a richer source of phosphorus, vitamin A, protein and contains high levels of natural antioxidants.
=== Drug Delivery === Microbubbles can serve as drug delivery vehicles in a variety of methods. The most notable of these include: (1) incorporating a lipophilic drug to the lipid monolayer, (2) attaching nanoparticles and liposomes to the microbubble surface, (3) enveloping the microbubble within a larger liposome, and (4) electrostatically bonding nucleic acids to the microbubble surface.
== Governing board == The governing board of ECU Health sets the policies that govern the operation and direction of ECU Health, ECU Health Medical Center and its subsidiaries. Members of the governing board meet monthly and are responsible for the articulation of its mission and values, the protection of assets and the quality of services. They serve voluntarily and without pay. Members of the governing board are chosen for their management experience and their standing as community leaders. They are chosen by the UNC Board of Governors and Pitt County Commissioners for a term of 5 years, not to exceed two consecutive terms. ECU Health Board of Directors:
Sources: en.wikipedia.org
One of the largest traditional markets in Taiwan, the Jianguo Market in Taichung, was torn down and replaced by a new facility in 2016. The new facilities provided better hygiene, disability accessibility, and refrigeration, but the relocation was initially met with hesitation from the local vendors before a grassroots outreach campaign led to greater acceptance.
Other methods of preservation include the storage of specimens in spirit. Such wet specimens have special value in physiological and anatomical study, apart from providing better quality of DNA for molecular studies. Freeze drying of specimens is another technique that has the advantage of preserving stomach contents and anatomy, although it tends to shrink, making it less reliable for morphometrics.
=== Whipple's triad === The symptoms of low blood sugar alone are not specific enough to characterize a hypoglycemic episode. A single blood sugar reading below 70 mg/dL is also not specific enough to characterize a hypoglycemic episode. Whipple's triad is a set of three conditions that need to be met to accurately characterize a hypoglycemic episode. The three conditions are the following:
In 1929, Adolf Butenandt and Edward Adelbert Doisy independently isolated and purified estrone, the first estrogen to be discovered. Then, estriol and estradiol were discovered in 1930 and 1933, respectively. Shortly following their discovery, estrogens, both natural and synthetic, were introduced for medical use. Examples include estriol glucuronide (Emmenin, Progynon), estradiol benzoate, conjugated estrogens (Premarin), diethylstilbestrol, and ethinylestradiol. The word estrogen derives from Ancient Greek. It is derived from "oestros" (a periodic state of sexual activity in female mammals), and genos (generating). It was first published in the early 1920s and referenced as "oestrin". With the years, American English adapted the spelling of estrogen to fit with its phonetic pronunciation.
=== Legality of the strikes === Experts have questioned the legality of the strikes under US and international law. The US Coast Guard or other law enforcement agencies had been responsible for US drug interdiction efforts for decades prior to the strikes, and suspects were prosecuted as a criminal matter, but according to CNN, the DOJ argued before the strikes began "that the president is legally allowed to authorize lethal strikes against 24 cartels and criminal organizations in self-defense, because the groups pose an imminent threat to Americans". Experts speaking to the BBC said that the 2 September strike was potentially illegal under international maritime and human rights law. Though the US is not a signatory to the United Nations Convention on the Law of the Sea, previous US policy had been to "act in a manner consistent with its provisions"; countries are not supposed to interfere with ships in international waters except in cases such as hot pursuit out of a country's territorial waters.
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.